![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, April 05, 2024 8:30:50 AM
In my opinion one wildcard is the Parkinsons Disease test. If AXIM sells a new marketing agreement with a big pharma for the Parkinsons disease test that should come with $$ millions in Up-front revenue and residual revenue for each test.
In my opinion that only happens if AXIM needs the Up-front cash = Now. The Up-front cash would be needed because Cash-flow positive is pushed out with only one new customer per week. It should be obvious to everyone that the Tear-based Point-of-Care quantitative Parkinsons disease test would be a great addition to the Verséa Ophthalmics marketing agreement.
The second wildcard is CLIA Waiver approvals. However it seems like Mr Huemoeller mentioned in so many words that the CLIA Waiver Application has not been started yet. AXIM needs help from Verséa Ophthalmics and/or Mr Kurt Phinney to produce the CLIA Waiver Application and the comparison study.
I guess a third wildcard could be a merger or acquisition.
Outside of a few wildcards AXIM is not cashflow positive for months and months. These are my opinions. I really like the potential I see in AXIM. I may increase my position in AXIM in August or later when funds are hopefully available. The stock price probably does not move until AXIM is closer to cashflow positive.
Good luck to all.
Not investment advice.
Don't invest money needed for food or rent or happiness.
Recent AXIM News
- Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend] • Edgar (US Regulatory) • 05/22/2024 08:53:56 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/20/2024 08:24:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 04:59:09 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:29:50 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 09/21/2023 03:07:21 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 08/31/2023 08:10:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 05:35:50 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 08:11:37 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM